16 Oct 2019 Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS
16 Oct 2019 Amphivena Initiates Solid Tumor Clinical Trial
16 Oct 2019 Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
15 Oct 2019 PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
15 Oct 2019 Affimed Reports Progress on Key Clinical Development Programs
15 Oct 2019 Immutep reports positive final efficacy data from TACTI-mel trial in melanoma
14 Oct 2019 I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
14 Oct 2019 Femtogenix Presents Efficacy and Toxicity Data on Antibody Drug Conjugates Containing New Generation of DNA-binding Therapeutic Payloads
14 Oct 2019 Phase III PEMPHIX Study Shows Genentech’s Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
11 Oct 2019 Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
10 Oct 2019 Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
10 Oct 2019 Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer
10 Oct 2019 Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
09 Oct 2019 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
09 Oct 2019 Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma
09 Oct 2019 Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg
08 Oct 2019 ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
08 Oct 2019 Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
07 Oct 2019 Janssen Submits Application to U.S. FDA Seeking Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
04 Oct 2019 New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
04 Oct 2019 I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
04 Oct 2019 FASENRA (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™
03 Oct 2019 Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
02 Oct 2019 Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
02 Oct 2019 Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up